Lupus Nephritis After First-Line Therapy Failure in Rapidly Progressive Glomerulonephritis

This protocol addresses a severe and specific subset of lupus nephritis: patients presenting with rapidly progressive glomerulonephritis (RPGN) — a rapid decline in kidney function accompanied by histologic evidence of extensive crescent formation affecting more than 50% of glomeruli — in whom initial treatment has not achieved the required response.

Clinical scenario

Rapidly progressive glomerulonephritis with rapid decline in kidney function and biopsy evidence of extensive crescent formation affecting more than 50% of glomeruli. This is among the most aggressive presentations of lupus nephritis and demands prompt, structured escalation of management.

When initial therapy has not achieved the target response

First-line therapy in this setting typically includes IV pulse methylprednisolone followed by oral prednisone, combined with high-dose IV cyclophosphamide, and subsequently maintenance immunosuppression with mycophenolate mofetil, mycophenolate sodium, or azathioprine, alongside background hydroxychloroquine.

Escalation to the next treatment line is indicated when the following targets have not been met:

Kidney function not sufficiently preserved: GFR below 80% of baseline within 3 months
Proteinuria not adequately reduced: less than 25% by 3 months, or less than 50% by 6 months
Urine protein-to-creatinine ratio (UPCR) not reaching <700 mg/g by 12 months
No complete renal response (UPCR <500 mg/g) achieved

Next-line approach

The protocol describes switching to an alternative immunosuppressive and/or biologic regimen. In this context, combination therapy should be strongly considered over monotherapy. Referral to expert centres is recommended. The specific options and clinical decision algorithm are available in the full protocol.

Treatment response targets

Preservation or improvement of kidney function with GFR ≥80% of baseline within 3 months
Proteinuria reduction of at least 25% by 3 months and 50% by 6 months
UPCR <700 mg/g by 12 months
Complete renal response: UPCR <500 mg/g

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.ard.2025.09.007

This recommendation refers to the specific subset of patients who present with rapidly progressive glomerulonephritis, ie, a rapid decline in kidney function accompanied by histologic evidence of extensive crescent formation (typically affecting >50% of the glomeruli).

For patients with persistently active or relapsing disease, switching among different immunosuppressive and/or biologic drugs and referral to experts is recommended.

Any of the alternative regimens outlined in recommendation #4 can be tried.

In cases of monotherapy with MPAA or CYC used as initial therapy, combination therapy should now be strongly considered.

Treatment should aim for optimisation (preservation or improvement) of kidney function within 3 months, accompanied by a reduction in proteinuria of at least 25% by 3 months, 50% by 6 months, and a UPCR target <700 mg/g by 12 months, and as low as possible afterwards.

Together with proteinuria, stabilisation (if not improvement) of GFR to ≥80% of baseline value is desirable within the first 3 months to ensure that the patient is not deteriorating and in need of reevaluation of the treatment regimen.

Complete renal response should be defined as UPCR <500 mg/g at any time point.

View source ↗